You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ILOSONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ilosone, and what generic alternatives are available?

Ilosone is a drug marketed by Lilly and Dista and is included in seven NDAs.

The generic ingredient in ILOSONE is erythromycin estolate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin estolate; sulfisoxazole acetyl profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ILOSONE?
  • What are the global sales for ILOSONE?
  • What is Average Wholesale Price for ILOSONE?
Summary for ILOSONE
US Patents:0
Applicants:2
NDAs:7
Raw Ingredient (Bulk) Api Vendors: 35
Patent Applications: 2,464
DailyMed Link:ILOSONE at DailyMed
Drug patent expirations by year for ILOSONE

US Patents and Regulatory Information for ILOSONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ILOSONE erythromycin estolate CAPSULE;ORAL 061897-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly ILOSONE erythromycin estolate SUSPENSION;ORAL 061894-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly ILOSONE erythromycin estolate SUSPENSION/DROPS;ORAL 061894-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly ILOSONE SULFA erythromycin estolate; sulfisoxazole acetyl SUSPENSION;ORAL 050599-001 Sep 29, 1989 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly ILOSONE erythromycin estolate SUSPENSION;ORAL 050010-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly ILOSONE erythromycin estolate CAPSULE;ORAL 061897-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dista ILOSONE erythromycin estolate FOR SUSPENSION;ORAL 061893-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.